Generation bio announces the presentation of preclinical data on iqdna and ctlnp platforms at the asgct 27th annual meeting

Cambridge, mass., may 09, 2024 (globe newswire) --   generation bio co. (nasdaq:gbio) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet dna (iqdna) and cell-targeted lipid nanoparticle (ctlnp) platforms as well as its enzymatic synthesis manufacturing at the american society of gene and cell therapy (asgct) 27th annual meeting. a sixth presentation on the company's ctlnp platform will be discussed in an oral presentation on saturday, may 11.
GBIO Ratings Summary
GBIO Quant Ranking